Physician profile
Jaudat Mahmood
NPI 1295154649
$96,711.69
in general payments reported to CMS, 2019-2025
23 companies · $42K in 2025
The $42K reported for 2025 was more than what 98% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,163 · 2020: $1,675 · 2021: $325 · 2022: $1,197 · 2023: $23K · 2024: $25K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $57K · Travel and Lodging: $28K · Food and Beverage: $5,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $56,908.80 |
| Travel and Lodging | $27,890.60 |
| Food and Beverage | $5,552.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $90,131.80 | 2019-2025 | Sprint Pns System |
| Nevro Corp. | $3,657.83 | 2019-2024 | Senza |
| Abbott Laboratories | $744.60 | 2022-2024 | Octrode, Proclaim |
| Averitas Pharma INC. | $455.33 | 2024-2025 | Qutenza |
| Medtronic, INC. | $267.44 | 2021-2025 | Intellis Adaptivestim |
| Vertos Medical, INC. | $234.65 | 2022-2024 | Mild Device Kit |
| Boston Scientific Corporation | $133.93 | 2019-2023 | |
| Painteq LLC | $131.16 | 2023-2024 | Painteq |
| Stryker Corporation | $130.77 | 2022 | |
| Collegium Pharmaceutical, INC. | $125.25 | 2021-2024 | Belbuca |
| Insmed, INC. | $125.00 | 2019 | |
| Nalu Medical, INC. | $114.47 | 2022-2023 | Nalu Neurostimulation System |
| Si-Bone, INC. | $91.57 | 2021-2025 | |
| Biodelivery Sciences International, INC. | $65.55 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $62.92 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $59.43 | 2023 | Intracept |
| Pacira Pharmaceuticals Incorporated | $41.75 | 2022-2025 | Exparel |
| Curonix LLC | $37.88 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Depuy Synthes Sales INC. | $30.99 | 2022 | |
| Pacira Therapeutics, INC. | $24.31 | 2021 | |
| Hydrocision, INC. | $15.78 | 2021 | |
| Saluda Medical Americas, INC. | $15.26 | 2025 | Evoke |
| International Rehabilitative Sciences, INC | $14.02 | 2024 | Rs 4i Plus Sequential Stimulator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaudat Mahmood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.